Tafinlar(dabrafenib)
Tafinlar (dabrafenib) is a small molecule pharmaceutical. Dabrafenib was first approved as Tafinlar on 2013-05-29. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma. The pharmaceutical is active against serine/threonine-protein kinase B-raf.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Tafinlar
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tafinlar | New Drug Application | 2024-07-11 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DABRAFENIB MESYLATE, TAFINLAR, NOVARTIS | |||
| 2030-03-16 | ODE-428 | ||
| 2026-03-16 | I-908, NP | ||
| 2025-12-22 | PED | ||
| 2025-11-04 | PED | ||
| 2025-10-30 | PED | ||
| 2025-06-22 | I-894 | ||
| 2025-05-04 | ODE-183 | ||
| 2025-04-30 | ODE-182 | ||
| 2024-12-22 | PED | ||
| 2024-06-22 | ODE-147 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Dabrafenib Mesylate, Tafinlar, Novartis | |||
| 11504333 | 2038-06-29 | DP | |
| 10869869 | 2033-08-30 | U-3185 | |
| 8703781 | 2030-10-15 | DS, DP | U-1713, U-2032, U-2296, U-2298, U-3565 |
| 8952018 | 2030-10-15 | U-2027 | |
| 7994185 | 2030-01-20 | DS, DP | U-1406, U-2031, U-2032, U-2296 |
| 8415345 | 2030-01-20 | DS, DP | U-1406, U-2031, U-2032, U-2296 |
| 9233956 | 2029-05-04 | U-1811, U-2031, U-2032, U-2296 | |
| 8835443 | 2025-06-10 | U-2026, U-2027, U-2296, U-2298, U-3565 | |
HCPCS
No data
Clinical
Clinical Trials
172 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 28 | 46 | 8 | 1 | 21 | 92 |
| Neoplasms | D009369 | — | C80 | 20 | 21 | 1 | 1 | 3 | 42 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 2 | 13 | 2 | 1 | 1 | 19 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | 2 | 13 | 2 | 1 | 1 | 19 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 4 | — | 1 | 4 | 9 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 5 | — | 1 | 2 | 8 |
| Glioma | D005910 | EFO_0000520 | — | 1 | 4 | — | 1 | 1 | 6 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 2 | — | 1 | 2 | 5 |
| Astrocytoma | D001254 | EFO_0000271 | — | — | 2 | — | 1 | 1 | 4 |
| Neurofibromatoses | D017253 | — | Q85.00 | 2 | 2 | — | 1 | — | 3 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cutaneous malignant melanoma | D000096142 | — | — | 4 | 8 | 2 | — | 1 | 13 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 4 | 8 | 1 | — | — | 11 |
| Adamantinoma | D050398 | — | — | — | 3 | 1 | — | — | 4 |
| Ameloblastoma | D000564 | — | — | — | 2 | 1 | — | — | 3 |
| Fever | D005334 | HP_0001945 | R50.9 | — | 1 | 1 | — | — | 2 |
| Hyperthermia | D000084462 | — | — | — | 1 | 1 | — | — | 2 |
| Sarcoma | D012509 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 4 | 8 | — | — | 1 | 12 |
| Carcinoma | D002277 | — | C80.0 | 3 | 5 | — | — | 2 | 10 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | 5 | — | — | 1 | 7 |
| Anaplastic thyroid carcinoma | D065646 | — | — | 1 | 5 | — | — | — | 6 |
| Hematologic neoplasms | D019337 | — | — | 2 | 4 | — | — | — | 5 |
| Colorectal neoplasms | D015179 | — | — | 2 | 3 | — | — | 1 | 5 |
| Recurrence | D012008 | — | — | 1 | 1 | — | — | 2 | 4 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 2 | — | — | — | 4 |
| Lymphoma | D008223 | — | C85.9 | 1 | 2 | — | — | — | 3 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 1 | — | — | — | 3 |
Show 30 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoid leukemia | D007945 | — | C91 | 1 | — | — | — | 2 | 3 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | 1 | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | 1 | 2 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 1 | — | — | — | 1 | 2 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | 1 | 2 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | 1 | 2 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 2 | — | — | — | — | 2 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
Show 20 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute disease | D000208 | — | — | — | — | — | — | 1 | 1 |
| Small cell lung carcinoma | D055752 | — | — | — | — | — | — | 1 | 1 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | — | 1 | 1 |
| Eunuchism | D005058 | EFO_0007266 | E29.1 | — | — | — | — | 1 | 1 |
| Hypogonadism | D007006 | HP_0000044 | E23.0 | — | — | — | — | 1 | 1 |
| Physiological sexual dysfunction | D012735 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dabrafenib |
| INN | dabrafenib |
| Description | Dabrafenib is an organofluorine compound and antineoplastic agent, used as its mesylate salt in treatment of metastatic melanoma. It has a role as an antineoplastic agent, a B-Raf inhibitor and an anticoronaviral agent. It is a sulfonamide, an organofluorine compound, a member of 1,3-thiazoles and an aminopyrimidine. |
| Classification | Small molecule |
| Drug class | rapidly accelerated fibrosarcoma (RAF) kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1 |
Identifiers
| PDB | — |
| CAS-ID | 1195765-45-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2028663 |
| ChEBI ID | 75045 |
| PubChem CID | 44462760 |
| DrugBank | DB08912 |
| UNII ID | QGP4HA4G1B (ChemIDplus, GSRS) |
Target
Agency Approved
BRAF
BRAF
Organism
Homo sapiens
Gene name
BRAF
Gene synonyms
BRAF1, RAFB1
NCBI Gene ID
Protein name
serine/threonine-protein kinase B-raf
Protein synonyms
94 kDa B-raf protein, B-Raf proto-oncogene serine/threonine-protein kinase (p94), B-Raf serine/threonine-protein, murine sarcoma viral (v-raf) oncogene homolog B1, p94, Proto-oncogene B-Raf, v-raf murine sarcoma viral oncogene homolog B, v-Raf murine sarcoma viral oncogene homolog B1
Uniprot ID
Mouse ortholog
Braf (109880)
serine/threonine-protein kinase B-raf (P28028)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,136 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
18,230 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use